Filtered By:
Cancer: Lymphoma
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 62 results found since Jan 2013.
Antitumor efficacy of multi-target < em > in situ < /em > vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers
J Biomed Res. 2022 Nov 28:1-19. doi: 10.7555/JBR.36.20220052. Online ahead of print.ABSTRACTTo overcome immune tolerance to cancer, the immune system needs to be exposed to a multi-target action intervention. Here, we investigated the activating effect of CpG oligodeoxynucleotides (ODNs), mesyl phosphoramidate CpG ODNs, anti-OX40 antibodies, and OX40 RNA aptamers on major populations of immunocompetent cells ex vivo. Comparative analysis of the antitumor effects of in situ vaccination with CpG ODNs and anti-OX40 antibodies, as well as several other combinations, such as mesyl phosphoramidate CpG ODNs and OX40 RNA aptamers,...
Source: Biomed Res - May 10, 2023 Category: Research Authors: Anastasia S Proskurina Vera S Ruzanova Genrikh S Ritter Yaroslav R Efremov Zakhar S Mustafin Sergey A Lashin Ekaterina A Burakova Alesya A Fokina Timofei S Zatsepin Dmitry A Stetsenko Olga Y Leplina Alexandr A Ostanin Elena R Chernykh Sergey S Bogachev Source Type: research
Epstein ‒Barr virus-associated cellular immunotherapy
Cytotherapy. 2023 May 6:S1465-3249(23)00099-3. doi: 10.1016/j.jcyt.2023.04.003. Online ahead of print.ABSTRACTEpstein‒Barr virus (EBV) is a human herpes virus that is saliva-transmissible and universally asymptomatic. It has been confirmed that more than 90% of the population is latently infected with EBV for life. EBV can cause a variety of related cancers, such as nasopharyngeal carcinoma, diffuse large B-cell lymphoma, and Burkitt lymphoma. Currently, many clinical studies have demonstrated that EBV-specific cytotoxic T lymphocytes and other cell therapies can be safely and effectively transfused to prevent and treat ...
Source: Herpes - May 7, 2023 Category: Infectious Diseases Authors: Yi Zhang Hairong Lyu Ruiting Guo Xinping Cao Juan Feng Xin Jin Wenyi Lu Mingfeng Zhao Source Type: research
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study
CONCLUSION: Antibody response is lower in patients with indolent lymphomas compared to the general population. Lower Ab seropositivity was found in patients with a history of anti-leukemic agent therapy or those immunized with Pfizer vaccine. This data suggests that Moderna vaccination may confer a greater degree of immunity against SARS-CoV-2 in patients with indolent lymphomas.PMID:37141401 | DOI:10.1093/oncolo/oyad121
Source: The Oncologist - May 4, 2023 Category: Cancer & Oncology Authors: Peter G Doukas Frederique St Pierre Reem Karmali Xinlei Mi Jennifer Boyer Mariana Nieves Michael G Ison Jane N Winter Leo I Gordon Shuo Ma Source Type: research
Risk Factors and Trends for HPV-Associated Subsequent Malignant Neoplasms among Adolescent and Young Adult Cancer Survivors
CONCLUSIONS: HPV-SMN in AYA survivors are driven by oropharyngeal cancers despite temporal declines in oropharyngeal-SMN. Hispanic survivors are at risk for cervical-SMN relative to the general population.IMPACT: Encouraging HPV vaccination and cervical and oral cancer screenings may reduce HPV-SMN burden among AYA survivors.PMID:37071501 | DOI:10.1158/1055-9965.EPI-22-0826
Source: Cancer Control - April 18, 2023 Category: Cancer & Oncology Authors: Judy Y Ou Natalie Bennion Kellee Parker Douglas Fair Heidi A Hanson Deanna Kepka Echo L Warner Joemy M Ramsay Heydon K Kaddas Anne C Kirchhoff Source Type: research
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 Mar 7:S2152-2650(23)00076-9. doi: 10.1016/j.clml.2023.03.002. Online ahead of print.ABSTRACTCOVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about ...
Source: Clinical Lymphoma and Myeloma - April 1, 2023 Category: Cancer & Oncology Authors: Julia E Wiedmeier-Nutor Madiha Iqbal Allison C Rosenthal Evandro D Bezerra Juan Esteban Garcia-Robledo Radhika Bansal Patrick B Johnston Matthew Hathcock Jeremy T Larsen P Leif Bergsagel Yucai Wang Craig B Reeder Jose F Leis Rafael Fonseca Jeanne M Palmer Source Type: research
Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
This study evaluates the public health impact of recombinant zoster vaccine (RZV) relative to no HZ vaccination for the prevention of HZ among adults aged ≥18 years diagnosed with selected cancers in the United States (US). A static Markov model was used to simulate three cohorts of individuals who are IC with cancer (time horizon of 30 years; one-year cycle length): hematopoietic stem cell transplant (HSCT) recipients, patients with breast cancer (BC; a solid tumor example), and patients with Hodgkin's lymphoma (HL; a hematological malignancy example). Cohort sizes reflect the estimated annual incidence of each conditio...
Source: Herpes - March 7, 2023 Category: Infectious Diseases Authors: Desmond Curran Brandon J Patterson Justin Carrico Ahmed Salem Elizabeth M La St éphane Lorenc Katherine A Hicks Sara Poston Christopher F Carpenter Source Type: research
